| Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological … SH Kennedy, RW Lam, RS McIntyre, SV Tourjman, V Bhat, P Blier, ... The Canadian Journal of Psychiatry 61 (9), 540-560, 2016 | 1227 | 2016 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake … JK Hicks, JR Bishop, K Sangkuhl, DJ Müller, Y Ji, SG Leckband, ... Clinical Pharmacology & Therapeutics 98 (2), 127-134, 2015 | 1021 | 2015 |
| Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update JK Hicks, K Sangkuhl, JJ Swen, VL Ellingrod, DJ Müller, K Shimoda, ... Clinical pharmacology and therapeutics 102 (1), 37, 2017 | 671 | 2017 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants JK Hicks, JJ Swen, CF Thorn, K Sangkuhl, ED Kharasch, VL Ellingrod, ... Clinical Pharmacology & Therapeutics 93 (5), 402-408, 2013 | 530 | 2013 |
| Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process KE Caudle, TE Klein, JM Hoffman, DJ Müller, M Whirl-Carrillo, L Gong, ... Current drug metabolism 15 (2), 209, 2014 | 458 | 2014 |
| Molecular mechanisms of schizophrenia UE Lang, I Puls, DJ Müller, N Strutz-Seebohm, J Gallinat Cellular Physiology and Biochemistry 20 (6), 687-702, 2007 | 400 | 2007 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy KR Crews, AA Monte, R Huddart, KE Caudle, ED Kharasch, A Gaedigk, ... Clinical Pharmacology & Therapeutics 110 (4), 888-896, 2021 | 329 | 2021 |
| Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications TAP Lett, TJM Wallace, NI Chowdhury, AK Tiwari, JL Kennedy, DJ Müller Molecular Psychiatry 17 (3), 242-266, 2011 | 302 | 2011 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update EJ Phillips, C Sukasem, M Whirl‐Carrillo, DJ Müller, HM Dunnenberger, ... Clinical Pharmacology & Therapeutics 103 (4), 574-581, 2018 | 281 | 2018 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing SG Leckband, JR Kelsoe, HM Dunnenberger, AL George Jr, E Tran, ... Clinical Pharmacology & Therapeutics 94 (3), 324-328, 2013 | 270 | 2013 |
| Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder TG Schulze, DJ Müller, H Krauss, H Scherk, S Ohlraun, YV Syagailo, ... American Journal of Medical Genetics 96 (6), 801-803, 2000 | 242 | 2000 |
| Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia NE MacKenzie, C Kowalchuk, SM Agarwal, KA Costa-Dookhan, ... Frontiers in psychiatry 9, 622, 2018 | 216 | 2018 |
| Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug–induced weight gain AK Malhotra, CU Correll, NI Chowdhury, DJ Müller, PK Gregersen, ... Archives of general psychiatry 69 (9), 904-912, 2012 | 215 | 2012 |
| Comprehensive allelotype and genetic analysis of 466 human nervous system tumors A von Deimling, R Fimmers, MC Schmidt, B Bender, F Fassbender, ... Journal of Neuropathology & Experimental Neurology 59 (6), 544-558, 2000 | 211 | 2000 |
| Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting LV Kalman, JAG Agúndez, ML Appell, JL Black, GC Bell, S Boukouvala, ... Clinical Pharmacology & Therapeutics 99 (2), 172-185, 2016 | 207 | 2016 |
| An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ... Pharmacopsychiatry 55 (02), 73-86, 2022 | 202 | 2022 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy JT Brown, JR Bishop, K Sangkuhl, EL Nurmi, DJ Mueller, JC Dinh, ... Clinical Pharmacology & Therapeutics 106 (1), 94-102, 2019 | 201 | 2019 |
| MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes JP Lopez, LM Fiori, C Cruceanu, R Lin, B Labonte, HM Cates, EA Heller, ... Nature communications 8 (1), 15497, 2017 | 187 | 2017 |
| Genetics of antipsychotic treatment emergent weight gain in schizophrenia DJ Müller, JL Kennedy Pharmacogenomics 7 (6), 863-887, 2006 | 185 | 2006 |
| Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. V De Luca, AHC Wong, DJ Muller, GW Wong, RF Tyndale, JL Kennedy Neuropsychopharmacology 29 (8), 1522-1526, 2004 | 177 | 2004 |
James L KennedyProfessor of Psychiatry, Centre for Addiction and Mental Health, University of TorontoEmail verificata su camh.ca
